By Meg Flippin Benzinga
DETROIT, MICHIGAN - April 22, 2025 (NEWMEDIAWIRE) - From protecting against infections for people who had a solid organ or bone marrow transplant to treating hepatitis B infection, or preventing deadly Rabies disease in individuals who were exposed to a suspected rabid animal, specialty plasma products are used by healthcare providers around the world to save thousands of lives every day. Kamada Ltd. (NASDAQ: KMDA), a global biopharmaceutical company and a leader in the specialty plasma-derived field, is rising up to meet that demand and expanding its specialty hyper-immune plasma collection.
The company recently announced the opening of its third plasma collection center. The 11,100-square-foot center in San Antonio, Texas, will be operated by the company’s plasma unit and is planned to support as many as 50 donor beds. The facility is projected to collect up to 50,000 liters annually, adding to Kamada’s supply at a time when specialty plasma, particularly hyper-immune plasma, is needed.
The site requires approvals from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which the company expects within nine to twelve months of submitting applications, which it is targeting during the second half of 2025. The site will be staffed with what Kamada says is a team of skilled and experienced plasma collection specialists.
Using Human Plasma To Fight Infections, Prevent Disease
Hyper-immune plasma contains antibodies extracted from a pool of human donors that have high concentrations of specific antibodies. Purified antibodies from hyper-immune plasma, such as anti-rabies and anti-CMV, are used to reduce the risk of infection and the severity of certain diseases.
“We are extremely pleased to announce the opening of our new state-of-the-art plasma collection center in San Antonio, Texas,” said Amir London, CEO of Kamada. “The opening of this center will expand our collection capacity of specialty plasma, such as Anti-Rabies and Anti-D, for our internal use beyond our existing sites in Beaumont and Houston. The collected specialty plasma will support our increasing demand for hyper-immune plasma and is expected to lower our raw material costs.”
Mr. London said the new center will also collect normal source plasma to be sold to other companies for the manufacturing of plasma-derived medicines. Once at full capacity, Kamada expects the center to contribute annual revenues of $8 million to $10 million in sales of normal source plasma.
Kamada All In With Plasma Therapeutics
As it stands, to date the FDA has approved six of Kamada's plasma-derived therapeutics, which target rare and underserved conditions such as exposure to potentially rabid animals, lung disease as a result of Alpha-1 antitrypsin deficiency (AATD), exposure of immune-compromised patients to the Varicella virus and infectious diseases after solid organ transplantation (such as CMV and hepatitis B). By developing its own plasma collection capabilities, Kamada says it reduces some of the dependency on third-party suppliers, expects to improve its cost of goods and can be a supplier for industry peers.
Last September, Kamada announced the opening of its second plasma collection site in Houston, Texas. Similar to the one opened in San Antonio, the Houston facility is 12,000 square feet, can support over 50 donor beds and has the capacity to collect up to 50,000 liters annually. When announcing that facility, Kamada said it was expected to be one of the largest sites for the collection of specialty plasma in the U.S. Kamada also operates an FDA-licensed plasma collection center in Beaumont, Texas.
From developing specialty plasma therapeutics to opening plasma collection sites, Kamada is positioning itself to be a leading player in the field of specialty plasma-derived therapeutics.
Featured image courtesy of Kamada Pharmaceuticals.
This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.
This post includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including (among others) statements regarding: 1) the San Antionio facility will also collect normal source plasma to be sold to other companies which manufacture plasma-derived medicines and once fully operational, such new facility would contribute revenue to the tune of $8 million to $10 million annually in the sales of normal source plasma, 2) each of the Houston facility and the new facility in San Antonio is planned to support as many as 50 donor beds and has planned annual collection capacity of about 50,000 liters, 3) expectation to receive FDA and EMA approvals during the second half of 2025, 4) the opening of the new site in San Antonio will expand the company's collection capacity of specialty plasma, such as Anti-Rabies and Anti-D, for our internal use beyond the company's existing sites in Beaumont and Houston, 5) the collected specialty plasma will support the company's increasing demand for hyper-immune plasma and is expected to lower its raw material costs, 6) by developing its own plasma collection capabilities, the company will reduce some of the dependency on third-party suppliers and improve its cost of goods, and will enable it to be a supplier for industry peers, and 7) the company's expectation to be one of the largest sites for the collection of specialty plasma in the U.S. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, conflicts in the Middle East and the impact of such conflicts, continued demand for Kamada’s products, financial conditions of the Company’s customers, suppliers and service providers, Kamada’s ability to leverage new business opportunities and integrate the new product portfolio into its current product portfolio, Kamada’s ability to reap the benefits of the acquisition and expansion of plasma collection centers, Kamada’s ability to continue enrollment of the pivotal Phase 3 InnovAATe clinical trial, unexpected results of clinical studies, Kamada’s ability to manage operating expenses, additional competition in the markets that Kamada competes, regulatory delays, and other risks detailed in Kamada’s filings with the U.S. Securities and Exchange Commission (the “SEC”) and available at the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
This content was originally published on Benzinga. Read further disclosures here.
View the original release on www.newmediawire.com
